KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Payables (2016 - 2025)

Amgen has reported Payables over the past 17 years, most recently at $2.4 billion for Q4 2025.

  • Quarterly results put Payables at $2.4 billion for Q4 2025, up 24.06% from a year ago — trailing twelve months through Dec 2025 was $2.4 billion (up 24.06% YoY), and the annual figure for FY2025 was $2.4 billion, up 24.06%.
  • Payables for Q4 2025 was $2.4 billion at Amgen, down from $2.8 billion in the prior quarter.
  • Over the last five years, Payables for AMGN hit a ceiling of $3.0 billion in Q2 2025 and a floor of $1.2 billion in Q3 2021.
  • Median Payables over the past 5 years was $1.5 billion (2022), compared with a mean of $1.7 billion.
  • Biggest five-year swings in Payables: decreased 5.92% in 2023 and later soared 87.05% in 2024.
  • Amgen's Payables stood at $1.4 billion in 2021, then grew by 15.08% to $1.6 billion in 2022, then rose by 1.15% to $1.6 billion in 2023, then increased by 20.0% to $1.9 billion in 2024, then grew by 24.06% to $2.4 billion in 2025.
  • The last three reported values for Payables were $2.4 billion (Q4 2025), $2.8 billion (Q3 2025), and $3.0 billion (Q2 2025) per Business Quant data.